Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/POR_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/POR_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/POR_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/POR_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/POR_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/POR_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0097305112 | Skin | cSCC | response to alcohol | 83/4864 | 253/18723 | 8.81e-03 | 4.05e-02 | 83 |
GO:00323502 | Skin | cSCC | regulation of hormone metabolic process | 16/4864 | 35/18723 | 9.09e-03 | 4.16e-02 | 16 |
GO:00713988 | Skin | cSCC | cellular response to fatty acid | 17/4864 | 38/18723 | 9.41e-03 | 4.25e-02 | 17 |
GO:000600610 | Skin | cSCC | glucose metabolic process | 66/4864 | 196/18723 | 9.75e-03 | 4.32e-02 | 66 |
GO:009013025 | Skin | cSCC | tissue migration | 115/4864 | 365/18723 | 9.81e-03 | 4.33e-02 | 115 |
GO:000166727 | Skin | cSCC | ameboidal-type cell migration | 146/4864 | 475/18723 | 1.05e-02 | 4.58e-02 | 146 |
GO:00060916 | Stomach | GC | generation of precursor metabolites and energy | 88/1159 | 490/18723 | 6.82e-20 | 9.27e-17 | 88 |
GO:00229006 | Stomach | GC | electron transport chain | 41/1159 | 175/18723 | 7.75e-14 | 4.68e-11 | 41 |
GO:00525476 | Stomach | GC | regulation of peptidase activity | 67/1159 | 461/18723 | 5.35e-11 | 1.10e-08 | 67 |
GO:00525486 | Stomach | GC | regulation of endopeptidase activity | 63/1159 | 432/18723 | 1.76e-10 | 2.82e-08 | 63 |
GO:00066315 | Stomach | GC | fatty acid metabolic process | 55/1159 | 390/18723 | 8.63e-09 | 8.38e-07 | 55 |
GO:00094106 | Stomach | GC | response to xenobiotic stimulus | 61/1159 | 462/18723 | 1.68e-08 | 1.43e-06 | 61 |
GO:00458616 | Stomach | GC | negative regulation of proteolysis | 50/1159 | 351/18723 | 2.96e-08 | 2.33e-06 | 50 |
GO:00513466 | Stomach | GC | negative regulation of hydrolase activity | 51/1159 | 379/18723 | 1.38e-07 | 8.14e-06 | 51 |
GO:20001166 | Stomach | GC | regulation of cysteine-type endopeptidase activity | 37/1159 | 235/18723 | 1.47e-07 | 8.52e-06 | 37 |
GO:00104666 | Stomach | GC | negative regulation of peptidase activity | 38/1159 | 262/18723 | 8.47e-07 | 4.18e-05 | 38 |
GO:00109516 | Stomach | GC | negative regulation of endopeptidase activity | 37/1159 | 252/18723 | 8.69e-07 | 4.26e-05 | 37 |
GO:00316676 | Stomach | GC | response to nutrient levels | 56/1159 | 474/18723 | 2.47e-06 | 1.06e-04 | 56 |
GO:00432816 | Stomach | GC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 31/1159 | 209/18723 | 5.31e-06 | 2.11e-04 | 31 |
GO:00462096 | Stomach | GC | nitric oxide metabolic process | 16/1159 | 81/18723 | 3.09e-05 | 8.48e-04 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POR | SNV | Missense_Mutation | | c.1987G>A | p.Asp663Asn | p.D663N | P16435 | protein_coding | tolerated(0.23) | benign(0.009) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
POR | SNV | Missense_Mutation | rs781866008 | c.838N>A | p.Asp280Asn | p.D280N | P16435 | protein_coding | deleterious(0.03) | benign(0.41) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | rs782053091 | c.709N>A | p.Glu237Lys | p.E237K | P16435 | protein_coding | deleterious(0.05) | benign(0.182) | TCGA-BH-A0AU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POR | SNV | Missense_Mutation | novel | c.893N>A | p.Gly298Glu | p.G298E | P16435 | protein_coding | deleterious(0.01) | benign(0.376) | TCGA-GM-A3NY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
POR | insertion | Frame_Shift_Ins | novel | c.937_938insG | p.Ser313CysfsTer6 | p.S313Cfs*6 | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | insertion | Nonsense_Mutation | novel | c.938_939insTTGAACCTGGGAGG | p.Lys314Ter | p.K314* | P16435 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
POR | deletion | Frame_Shift_Del | novel | c.1514_1524delAGAACGGCGGC | p.Glu505AlafsTer66 | p.E505Afs*66 | P16435 | protein_coding | | | TCGA-AC-A8OQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
POR | deletion | In_Frame_Del | | c.443_445delNNN | p.Thr149del | p.T149del | P16435 | protein_coding | | | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
POR | SNV | Missense_Mutation | rs367782552 | c.773C>T | p.Ala258Val | p.A258V | P16435 | protein_coding | tolerated(0.29) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
POR | SNV | Missense_Mutation | novel | c.1897N>T | p.Gly633Trp | p.G633W | P16435 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9U6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sirolimus | SIROLIMUS | 23974086 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | midazolam | MIDAZOLAM | 23324807,19801957 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | cyclosporine | CYCLOSPORINE | 29135906,24658827,24061445 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | zidovudine | ZIDOVUDINE | 22960662 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | atorvastatin | ATORVASTATIN | 25521355 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | nicotine | NICOTINE | |
5447 | POR | ENZYME, DRUGGABLE GENOME | | tacrolimus | TACROLIMUS | 23097010,25322286,26829596,30323313,24113216,26227094,21770725,24921414,24739669,25271728,24061445,28094348,29878980,29399716 |
5447 | POR | ENZYME, DRUGGABLE GENOME | | sunitinib | SUNITINIB | 28117434 |